Flow Eighteen38 reagent antibodies licensed for cancer research
Flow Eighteen38 and FairJourney Biologics (FJB) have announced an agreement with the Hubrecht Institute to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies to be used as research tools for the Hans Clevers group.
The Clevers group dedicates its activity to the study of the molecular mechanisms of tissue development and cancer of various organs using organoids made from adult Lgr5 stem cells. Under the agreement, Flow Eighteen38/FJB will provide the Clevers group at the Hubrecht Institute with research tools arising from an accelerated antibody research campaign that will support the group’s future scientific developments.
The reagent antibodies generated by Flow Eighteen38/FJB for the Hubrecht Institute comply with the recent EU recommendations on non-animal-derived antibodies and will be derived from FJB’s proprietary llama naïve libraries through its phage display technology platform. The Clevers group will benefit from the combination of this technology and the increased speed of delivery from this innovative approach, thought and optimised by the experienced scientists at Flow Eighteen38/FJB.